CZL-S092 is a PLK4 inhibitor with exceptional selectivity for other PLK4 family members (PLK1, PLK2, and PLK3), exhibiting an IC50 of 0.9 nM. It demonstrates antineuroblastoma activity in vitro (IMR-32, IC50 = 1.143 µM) and shows good oral bioavailability in vivo (SD rats, F = 22.1%). CZL-S092 is applicable in research on various cancers, including neuroblastoma.
Target:
PLK
* VAT and and shipping costs not included. Errors and price changes excepted
